Pharmacovigilance in Italy: An overview

Area of Science:

• Pharmacovigilance
• Drug Safety
• Regulatory Science

Background:

• Adverse drug reactions (ADRs) significantly contribute to morbidity and mortality.
• Underreporting of ADRs by healthcare professionals remains a critical issue globally and in Italy.
• Enhanced knowledge of pharmacovigilance and updated regulations are key to improving ADR detection and reporting.

Purpose of the Study:

• To examine the legislative framework governing pharmacovigilance in Italy.
• To assess how new regulations may impact the reporting of adverse drug reactions.
• To provide insights into the Italian pharmacovigilance system.

Main Methods:

• Information was gathered from scientific literature.
• Data was collected from official websites of the Italian Ministry of Health and the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA).

Main Results:

• European pharmacovigilance legislation was updated in 2010 (EU Regulation 1235/2010 and Directive 2010/84/EU).
• These legislative changes aim to enhance the efficiency, speed, and transparency of pharmacovigilance.
• The updated regulations clarify responsibilities and facilitate the circulation of ADR information.

Conclusions:

• Increased awareness of Italian pharmacovigilance legislation is crucial for improving ADR reporting rates.
• Promoting a culture of spontaneous reporting is essential for effective pharmacovigilance.
• Strengthening the pharmacovigilance system through regulatory clarity can lead to better drug safety outcomes.